Minimal residual disease is an independent predictor for 10-year survival in CLL-Reference-Cited by-同舟云学术

Minimal residual disease is an independent predictor for 10-year survival in CLL

Published:2016-12-15 Issue:24 Volume:128 Page:2770-2773
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Kwok Marwan¹²,Rawstron Andy C.¹,Varghese Abraham¹,Evans Paul A. S.¹,O’Connor Sheila J. M.¹,Doughty Chi¹,Newton Darren J.³,Moreton Paul¹,Hillmen Peter³

Affiliation:

1. Haematological Malignancy Diagnostic Service, Department of Haematology, St. James’s University Hospital, Leeds, United Kingdom;

2. Centre for Clinical Haematology, Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom; and

3. Section of Experimental Haematology, Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, United Kingdom

Abstract

Key Points MRD negativity is a predictor for long-term progression-free and overall survival independent of the type and line of therapy. MRD negativity confers the greatest prognostic benefit when achieved in the frontline setting.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/128/24/2770/1358282/blood714162.pdf

Reference21 articles.

1. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines;Hallek;Blood,2008

2. International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia;Rawstron;Leukemia,2007

3. Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL;Rawstron;Leukemia,2013

4. A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study;Rawstron;Leukemia,2016

5. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival;Moreton;J Clin Oncol,2005

Cited by 113 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Predicting progression‐free survival from measurable residual disease in chronic lymphocytic leukemia;Clinical and Translational Science;2024-08

2. Minimal residual disease: premises before promises;Biology & Philosophy;2024-08

3. What clinicians should know about surrogate end points in hematologic malignancies;Blood;2024-07-04

4. Realizing precision medicine in chronic lymphocytic leukemia: Remaining challenges and potential opportunities;HemaSphere;2024-07

5. The role of trephine bone marrow biopsies in the era of measurable residual disease—Results from the CLL10 trial of the German CLL Study Group (GCLLSG);HemaSphere;2024-07